SyntheMed's REPEL-CV Approved for Use After Pediatric Cardiac Surgery


March 9, 2009

March 9, 2008 - Biomaterials company SyntheMed Inc. has received FDA approval of its pre-market approval (PMA) application for REPEL-CV Adhesion Barrier for use in pediatric cardiac surgery patients.

REPEL-CV is a bioresorbable adhesion barrier film based on SyntheMed’s proprietary polymer technology. When placed over the surface of the heart at the conclusion of an open-heart surgical procedure it is designed to reduce the severity of adhesions that form between the surface of the heart and adjacent tissue surfaces following the surgical procedure. REPEL-CV is designed to provide the therapeutic benefit and then degrade so that it is cleared from the surgical site.

In a randomized, controlled clinical trial conducted at 15 pediatric cardiac surgery centers throughout the U.S., over 70 percent of the REPEL-CV treated patients were completely free of clinically significant adhesions, the most severe grade of adhesions measured, as compared to less than 30 percent in the control patients.

For more information:

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.